Tag Archives: cancer

New Guidances from FDA for October 2012

FDA released four notable new guidances in October 2012, with a focus on guidances related to medical devices: Guidance: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs — Questions and Answers (R1) Guidance: FDA and … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , | Comments Off on New Guidances from FDA for October 2012

New FDA Guidances Released in May 2012

Here’s a list of the  guidances released by FDA in April 2012, compiled by Cato Research Scientist Elinore Mercer, Ph.D. Pediatric Information for X-ray Imaging Device Premarket Notifications (Draft) S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Pathologic Complete Response in … Continue reading

Posted in FDA, Industry News | Tagged , , , , , , , , , , , , | Comments Off on New FDA Guidances Released in May 2012

New Guidances from FDA – June 2011

Here’s a list of the guidances released by FDA in June 2011, compiled by Cato Research Regulatory Scientist Cathy Anderson. Q11 Development and Manufacture of Drug Substances (Draft) Applying Human Factors and Usability Engineering to Optimize Medical Device Design (Draft) … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , | Comments Off on New Guidances from FDA – June 2011

Bridging the Valley of Death: Bringing New Drugs from the Bench to the Clinic

To bring a new medicine to the stage of clinical trial testing requires on the order of $500,000 to one million dollars and then seven to ten years of clinical trials and around $800 million dollars before getting to market.  … Continue reading

Posted in Clinical Trials, Venture Capital | Tagged , , , , , , , , , , , , | Comments Off on Bridging the Valley of Death: Bringing New Drugs from the Bench to the Clinic

Conference Recap – Biomarker World Congress 2011

  Everywhere in the news today, we hear that we are in the era of personalized medicine – where new medicines will be tailor-made for individual patients.  Specifically, personalized medicine is dedicated to the concept hat the right drug is … Continue reading

Posted in Clinical Trials, Conferences and Meetings | Tagged , , , , , , , , , , | Comments Off on Conference Recap – Biomarker World Congress 2011